ERS Genomics licenses gene editing tech to FASMAC

By The Science Advisory Board staff writers

October 14, 2020 -- ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC of Japan.

Under the terms of the nonexclusive agreement, FASMAC acquires the rights to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

FASMAC was established in 2001 to provide food analysis and biotechnology products and services, including DNA and RNA synthesis products, DNA sequencing services, food testing services, and genetic analysis reagents and kits.

If you like this content, please share it with a colleague!

Related Reading

ERS Genomics inks licensing agreement with Applied StemCell
ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.

Opposition fails for key CRISPR patent in Europe
ERS Genomics announced on February 10 that the European Patent Office has upheld an important CRISPR patent, rejecting opposition filed by anonymous parties.

ERS Genomics licenses CRISPR tech to Aelian
ERS Genomics announced on February 11 that it has entered an agreement to license its portfolio of CRISPR technology to Aelian Biotechnology.